News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Takeda preps for further acquisition Japanese firm has set money aside for emerging markets M&A.
News Pfizer looks to M&A after results disappointment Pfizer is looking to deals to keep investors onside after a disappointing set of Q4 results.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
